title: Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome.
abstract: Pathophysiological mechanisms of peripartum cardiomyopathy are not yet completely defined, although there is a strong association with various factors that are already known, including pre-eclampsia. Peripartum cardiomyopathy treatment follows the same recommendations as heart failure with systolic dysfunction. Clinical and experimental studies suggest that products of prolactin degradation can induce this cardiomyopathy. The pharmacological suppression of prolactin production by D2 dopamine receptor agonists bromocriptine and cabergoline has demonstrated satisfactory results in the therapeutic response to the treatment. Here we present a case of an adolescent patient in her first gestation with peripartum cardiomyopathy that evolved to the normalized left ventricular function after cabergoline administration, which was used as an adjuvant in cardiac dysfunction treatment. Subsequently, despite a short interval between pregnancies, the patient exhibited satisfactory progress throughout the entire gestation or puerperium in a new pregnancy without any cardiac alterations. Dopamine agonists that are orally used and are affordable in most tertiary centers, particularly in developing countries, should be considered when treating peripartum cardiomyopathy cases.
authors.affiliation: Fetal Medicine Service, Maternidade-Escola Assis Chateaubriand, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Maria Adélia Medeiros E
authors.initials: MA
authors.lastname: Melo
authors.affiliation: Fetal Medicine Service, Maternidade-Escola Assis Chateaubriand, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Jordão Sousa
authors.initials: JS
authors.lastname: Carvalho
authors.affiliation: Fetal Medicine Service, Maternidade-Escola Assis Chateaubriand, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Francisco Edson de Lucena
authors.initials: FE
authors.lastname: Feitosa
authors.affiliation: Department of Obstetrics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
authors.forename: Edward
authors.initials: E
authors.lastname: Araujo Júnior
authors.affiliation: Department of Obstetrics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
authors.forename: Alberto Borges
authors.initials: AB
authors.lastname: Peixoto
authors.affiliation: Fetal Medicine Service, Maternidade-Escola Assis Chateaubriand, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Francisco Herlânio
authors.initials: FH
authors.lastname: Costa Carvalho
authors.affiliation: Fetal Medicine Service, Maternidade-Escola Assis Chateaubriand, Universidade Federal do Ceará, Fortaleza, CE, Brazil.
authors.forename: Regina Coeli Marques
authors.initials: RC
authors.lastname: Carvalho
mesh_terms: D000293:Adolescent; D000077465:Cabergoline; D009202:Cardiomyopathies / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011644:Puerperal Disorders / Q000188:drug therapy*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline